NCT02909504 - Gao NARASD Lithium Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions

Bipolar Disorder

Interventions

DRUG

Lithium

Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L

Trial Locations (1)

University Hospitals Cleveland Medical Center Department of Psychiatry, Cleveland